Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC.PVLA · Entity 4452 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PALVELLA THERAPEUTICS, INC.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $102.19 · Expires 2036-06-10 | Direct | 3,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 3,000 · Balance 3,000 F1: The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | GrantStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $102.19 | $0.00 |
DisclosureSEC source: 0001104659-26-073420 · tm2617372-1_4seq1.xml · derivative · entry 1 Wessel Tadd S. · CIK 0002048706 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 00:00 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,350 | $0.00 Strike: $26.23 | $0.00 |
DisclosureSEC source: 0001583648-25-000042 · edgardoc.xml · derivative · entry 1 Wessel Tadd S. · CIK 0002048706 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,350 Underlying: Common Stock · 12,350 shares Expires 2035-06-10 Read SEC document |
| December 13, 2024 Filed Dec 18, 2024 01:45 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | GrantStock Option (right to buy) · Derivative | 24,700 | $0.00 Strike: $13.60 | $0.00 |
DisclosureSEC source: 0001062993-24-020822 · form4.xml · derivative · entry 1 Wessel Tadd S. · CIK 0002048706 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,700 Underlying: Common Stock · 24,700 shares Expires 2034-12-13 F1 · derivative.exercise_date: The stock options will vest and become exercisable in 36 equal monthly installments through the third anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.